Prospective non-interventional post authorization safety study (PASS) of idelalisib in Germany

First published: 27/04/2015
Last updated: 22/02/2024

Study | Finalised

Administrative details

PURI
https://redirect.ema.europa.eu/resource/44651

EU PAS number
EUPAS9564

Study ID
44651

DARWIN EU® study
No

Study countries
Germany

Study description
GS-DE-312-1750: This was a multicenter, non-interventional, two cohort (CLL and FL), prospective post authorization safety study (PASS) to evaluate the clinical effectiveness and safety of idelalisib for treatment of patients with Chronic Lymphocytic Leukemia (CLL) or Follicular Lymphoma (FL). This design was chosen to assess the effectiveness and safety of therapy with idelalisib up to 3 years per patient in clinical routine. The study enrolled adult patients with either CLL or FL with initiation of treatment with idelalisib alone or in combination with other antineoplastic agents and/or monoclonal antibodies in accordance with the approved label for Zydelig in the European Union (EU) and the current Zydelig EU SmPC. Participating study sites (hospitals and private practitioners) were specialized on treating oncology patients. All study sites were located in Germany. 87

medical centers distributed over all states of Germany participated in the study. The study included 179 adult patients with CLL or FL.

Study status
Finalised

Research institution and networks

Institutions

Gilead Sciences
First published: 12/02/2024
Last updated
12/02/2024
Institution
Pharmaceutical company

Multiple centres: 30 centres are involved in the study

Contact details

Study institution contact
Study Director Gilead
Study contact

ClinicalTrialDisclosure@gilead.com
Primary lead investigator
Study Director Gilead
Primary lead investigator

Study timelines

Date when funding contract was signed
Planned:
07/05/2015
Actual:

07/05/2015

Study start date
Planned:
30/09/2015
Actual:
30/09/2015

Data analysis start date
Planned:
31/12/2020

Date of interim report, if expected
Actual:
06/09/2017

Date of final study report
Planned:
31/12/2021
Actual:
10/09/2021

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Gilead Sciences

Study protocol

amd-4-prot-GS-DE-312-1750.pdf(1.62 MB)

protocol-GS-DE-312-1750-FINAL-COMPLETE.pdf(857.15 KB)

Regulatory

Was the study required by a regulatory body?
No

Is the study required by a Risk Management Plan (RMP)?
Not applicable

Methodological aspects

Study type

Study type list

Study topic:
Disease /health condition
Human medicinal product

Study type:
Non-interventional study

Scope of the study:
Drug utilisation
Effectiveness study (incl. comparative)
Safety study (incl. comparative)

Data collection methods:
Primary data collection

Main study objective:
The primary objectives of this study are to assess: Progression-Free Survival (PFS) (rate and time to progression) Overall Response Rate (ORR) Overall Survival (OS) (rate and survival duration)

Study Design

Non-interventional study design
Cohort

Study drug and medical condition

Medical condition to be studied
Chronic lymphocytic leukaemia
Follicular lymphoma

Population studied

Short description of the study population
The study population will include 300 adult patients (? 18 years) with Chronic lymphocytic leukaemia (CLL) or Follicular lymphoma (FL).

Inclusion Criteria CLL
1) Diagnosis of chronic lymphocytic leukemia (CLL) and decision for treatment with idelalisib
2) Indication approved for Zydelig in the European Union (EU) (refer to current Zydelig EU SmPC)
3) Understand and voluntarily sign an informed consent form
4) Male or female ?18 years of age at the time of signing the informed consent form

Exclusion Criteria CLL
1) Patients with suspected systemic bacterial, fungal or viral infection
2) Patients with history of another primary malignancy that is currently clinically significant or currently requires active intervention
3) Pregnant or breast feeding women
4) Concurrent participation in another therapeutic clinical trial

Inclusion / Exclusion Criteria FL (Cohort B)
Inclusion Criteria FL
1) Histopathologically confirmed diagnosis of Follicular Lymphoma and decision for treatment with idelalisib
2) Indication approved for Zydelig in the European Union (EU) (refer to current Zydelig EU SmPC)
3) Understand and voluntarily sign an informed consent form
4) Male or female ?18 years of age at the time of signing the informed consent form

Exclusion Criteria FL
1) Patients with suspected systemic bacterial, fungal or viral infection
2) Patients with history of another primary malignancy that is currently clinically significant or currently requires active intervention
3) Patients must not have received autologous stem cell transplant at least within 12 weeks prior to study treatment. If patients received autologous stem cell transplant more than 12 weeks ago, they must be fully recovered from the side effects of such treatment
4) Pregnant or breast feeding women
5) Concurrent participation in another therapeutic clinical trial

---

Age groups
Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Special population of interest
Other

Special population of interest, other
Chronic lymphocytic leukaemia (CLL) or Follicular lymphoma (FL) patients

Estimated number of subjects
179

Study design details

Outcomes
The primary objectives of this study are to assess: Progression-Free Survival (PFS) (rate and time to progression) Overall Response Rate (ORR) Overall Survival (OS) (rate and survival duration), Incidence of adverse drug reactions (ADRs), serious ADRs, fatal events (regardless of causality) and cause of death Incidence, risk factors, management & outcome of diarrhea/colitis, pneumonitis and liver enzyme elevation Type and incidence of Special Situation Reports Health resource utilization Patient Reported Outcome (health-related quality of life & health status)

Data analysis plan
Summary statistics were presented by cohort (CLL or FL) and included: -nominal variables: frequencies and percentages. -ordinal variables: frequencies, percentages, median, minimum and maximum. -continuous variables: number (N) of observations, mean, standard deviation, 25th percentile, median, 75th percentile, minimum and maximum. For ADR events, in addition to frequencies and percentages, incidence rate in person-time were calculated by dividing number of new cases by the total number of person-time at risk to account for varying length of follow-up. Kaplan-Meier plots of progression-free survival, overall response rate, and overall survival were produced. The median duration of progression-free survival, overall response rate, and overall survival were determined. If not otherwise specified, p-values were presented as two-sided and the level of significance was set to 5% (two-sided). 95%-confidence intervals were provided, where applicable.

Documents

Study results
GS-DE-312-1750-csr-abstract_f-redact.pdf(189.67 KB)

Data management

Data sources

Data sources (types)
Other

Data sources (types), other
Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping
No

Data quality specifications

Check conformance
Unknown

Check completeness
Unknown

Check stability
Unknown

Check logical consistency
Unknown

Data characterisation

Data characterisation conducted
No